Adaptimmune Reports Q1 Financial Results and Provides Business Update
Breadcrumb Trail Links Newsfile Article content TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$45 million …